文献速递儿科影像妇产影像US

全基因组测序在产前及婴儿期先天畸形中相较于染色体微阵列分析和外显子组测序的增量检出率:系统评价与Meta分析

Incremental yield of whole-genome sequencing over chromosomal microarray analysis and exome sequencing for congenital anomalies in prenatal period and infancy: systematic review and meta-analysis.
PubMed 文献 · Ultrasound Obstet Gynecol · 2024-01-01

系统评价与Meta分析纳入18项研究共902例存在产前超声可检出先天畸形的胎儿、新生儿或婴儿,评估全基因组测序(WGS)在QF-PCR/染色体微阵列分析(CMA)基础上及进一步在CMA和外显子组测序(ES)基础上的增量检出率。WGS相对QF-PCR/CMA的合并增量检出率为26%(95%CI 18-36%),相对CMA+ES仅为1%(95%CI 0-4%);WGS所需DNA量更少且周转时间可能更快,但意义不明变异(VUS)检出率较高。

要点

  • WGS在QF-PCR/CMA阴性先天畸形病例中的合并增量检出率为26%(95%CI 18-36%)。
  • WGS在QF-PCR/CMA和ES均阴性病例中的增量检出率仅1%(95%CI 0-4%)。
  • WGS所需DNA量为100±0 ng,少于QF-PCR/CMA和ES的350±50 ng(P=0.03)。

核心结论

  • WGS在先天畸形病例中前景广阔,但其相对ES的增量检出率尚未得到证实。
  • WGS所需DNA量少于序贯QF-PCR/CMA和ES,且周转时间可能更快。
  • WGS的意义不明变异(VUS)检出率相对较高。

研究设计与样本

  • 系统评价与Meta分析,2022年12月前瞻性注册,检索Ovid MEDLINE、EMBASE、MEDLINE(Web of Science)、Cochrane Library和ClinicalTrials.gov(2010年1月至2022年12月)。
  • 纳入标准为队列研究,包含3例及以上胎儿、新生儿或婴儿,具有一种及以上先天畸形、该畸形在产前超声可或本可检出、且QF-PCR和CMA阴性。
  • 共纳入18项研究902例合格病例,其中8项(44.4%)研究为产前队列共755例,其余为死后尸检胎儿或先天结构畸形新生儿/婴儿组成的产后队列。
  • 采用随机效应模型计算合并增量检出率,采用Higgins I²检验评估异质性。
  • 按产前或产后队列、多系统畸形病例及符合英国国家医疗服务体系(NHS England)产前ES纳入标准的病例进行亚组分析。

诊断标准与关键数值

  • WGS相对QF-PCR/CMA的合并增量检出率:全部病例26%(95%CI 18-36%,I²=86%),产前病例16%(95%CI 9-24%,I²=85%),产后病例39%(95%CI 27-51%,I²=53%)。
  • 符合NHS England产前ES纳入标准的病例WGS增量检出率为32%(95%CI 22-42%,I²=70%)。
  • 多系统畸形病例WGS增量检出率为30%(95%CI 19-43%,I²=65%)。
  • WGS对意义不明变异(VUS)的增量检出率为18%(95%CI 7-33%,I²=74%)。
  • WGS相对QF-PCR/CMA和ES的增量检出率为1%(95%CI 0-4%,I²=47%)。

临床应用与阅片要点

  • WGS在QF-PCR/CMA阴性的产前及产后先天畸形病例中可提供额外分子诊断信息,合并增量检出率26%。
  • 在已行CMA和ES均阴性的病例中,WGS的额外检出率仅1%,提示其作为序贯检测的附加价值有限。
  • WGS所需DNA量(100±0 ng)低于QF-PCR/CMA和ES(350±50 ng),P=0.03。
  • WGS合并中位周转时间为18天(范围1-912天)。

局限性

  • WGS相对ES的增量检出率尚未得到证实。
  • WGS的意义不明变异(VUS)检出率相对较高。
  • 各合并增量检出率存在异质性,全部病例I²=86%,产前病例I²=85%,产后病例I²=53%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: First, to determine the incremental yield of whole-genome sequencing (WGS) over quantitative fluorescence polymerase chain reaction (QF-PCR)/chromosomal microarray analysis (CMA) with and without exome sequencing (ES) in fetuses, neonates and infants with a congenital anomaly that was or could have been detected on prenatal ultrasound. Second, to evaluate the turnaround time (TAT) and quantity of DNA required for testing using these pathways.

METHODS: This review was registered prospectively in December 2022. Ovid MEDLINE, EMBASE, MEDLINE (Web of Science), The Cochrane Library and ClinicalTrials.gov databases were searched electronically (January 2010 to December 2022). Inclusion criteria were cohort studies including three or more fetuses, neonates or infants with (i) one or more congenital anomalies; (ii) an anomaly which was or would have been detectable on prenatal ultrasound; and (iii) negative QF-PCR and CMA. In instances in which the CMA result was unavailable, all cases of causative pathogenic copy number variants > 50 kb were excluded, as these would have been detectable on standard prenatal CMA. Pooled incremental yield was determined using a random-effects model and heterogeneity was assessed using Higgins' I2 test. Subanalyses were performed based on pre- or postnatal cohorts, cases with multisystem anomalies and those meeting the NHS England prenatal ES inclusion criteria.

RESULTS: A total of 18 studies incorporating 902 eligible cases were included, of which eight (44.4%) studies focused on prenatal cohorts, incorporating 755 cases, and the remaining studies focused on fetuses undergoing postmortem testing or neonates/infants with congenital structural anomalies, constituting the postnatal cohort. The incremental yield of WGS over QF-PCR/CMA was 26% (95% CI, 18-36%) (I2 = 86%), 16% (95% CI, 9-24%) (I2 = 85%) and 39% (95% CI, 27-51%) (I2 = 53%) for all, prenatal and postnatal cases, respectively. The incremental yield increased in cases in which sequencing was performed in line with the NHS England prenatal ES criteria (32% (95% CI, 22-42%); I2 = 70%) and in those with multisystem anomalies (30% (95% CI, 19-43%); I2 = 65%). The incremental yield of WGS for variants of uncertain significance (VUS) was 18% (95% CI, 7-33%) (I2 = 74%). The incremental yield of WGS over QF-PCR/CMA and ES was 1% (95% CI, 0-4%) (I2 = 47%). The pooled median TAT of WGS was 18 (range, 1-912) days, and the quantity of DNA required was 100 ± 0 ng for WGS and 350 ± 50 ng for QF-PCR/CMA and ES (P = 0.03).

CONCLUSION: While WGS in cases with congenital anomaly holds great promise, its incremental yield over ES is yet to be demonstrated. However, the laboratory pathway for WGS requires less DNA with a potentially faster TAT compared with sequential QF-PCR/CMA and ES. There was a relatively high rate of VUS using WGS. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Shreeve N, Sproule C, Choy KW, et al. Incremental yield of whole-genome sequencing over chromosomal microarray analysis and exome sequencing for congenital anomalies in prenatal period and infancy: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2024. PMID: 37725747. doi:10.1002/uog.27491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。